Analyst Consensus ?
1 unmapped firm rating excluded from the percentages.
The Procter & Gamble Company · PG · FY2026 Q3 · Calendar Q2 2026
P&G delivered a Q3 FY26 beat with EPS of $1.59 versus $1.56 estimated and revenue of $21.24B versus $20.53B estimated, as organic sales grew over 3% across all ten categories and seven regions. However, roughly $1 billion in after-tax cost headwinds from commodity, energy, and logistics pressures linked to Middle East geopolitical disruption are pressing margins. Management maintained FY26 guidance but now expects full-year EPS toward the lower end of the $6.83-$7.09 range. The stock saw a modest +0.92% abnormal return on the report day but drifted approximately 2.5% lower over the subsequent period, suggesting the market tempered its initial reception as the cost-pressure caveat sank in. At $148.66, the stock trades about 7% below the analyst consensus target of $159.75.
The Procter & Gamble Company, commonly referred to as P&G, is a global enterprise that supplies a broad spectrum of branded consumer products to markets worldwide. The company's operations are divided into five main business divisions: Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. The Beauty segment offers an assortment of hair care products, including conditioners, shampoos, styling aids, and treatments, under popular names like Head & Shoulders, Herbal Essences, Pantene, and Rejoice. It also features antiperspirants, deodorants, personal cleansing solutions, and skin care items from brands such as Olay, Old Spice, Safeguard, Secret, and SK-II. Within the Grooming division, P&G provides a range of shave care products and grooming appliances, prominently featuring brands like Braun, Gillette, and Venus. The Health Care unit encompasses oral hygiene essentials, including toothbrushes, toothpastes, and other dental care products sold under the Crest and Oral-B brand names.…
1 unmapped firm rating excluded from the percentages.
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Jul 28, 2026. Not an FN2 forecast.
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 21, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 16, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 10, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Apr 27, 2026 |
| UBS | Buy | Buy | Maintain | Apr 27, 2026 |
| TD Cowen | Hold | Hold | Maintain | Apr 27, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Apr 27, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Apr 8, 2026 |
| Deutsche Bank | Hold | Hold | Maintain | Mar 30, 2026 |
| Jefferies | Buy | Hold | Upgrade | Dec 17, 2025 |
| Freedom Broker | Hold | Hold | Maintain | Oct 29, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Oct 20, 2025 |
| BNP Paribas | Outperform | Outperform | Maintain | Aug 15, 2025 |
| Truist Securities | Buy | Buy | Maintain | Apr 25, 2025 |
| RBC Capital | Outperform | Sector Perform | Upgrade | Apr 25, 2025 |
| Morgan Stanley | Overweight | Overweight | Maintain | Apr 25, 2025 |
| Citigroup | Buy | Buy | Maintain | Apr 25, 2025 |
| Stifel | Hold | Hold | Maintain | Jan 23, 2025 |
| DA Davidson | Buy | Buy | Maintain | Jan 23, 2025 |
| DZ Bank | Buy | Hold | Upgrade | Aug 29, 2024 |
| Argus Research | Buy | Buy | Maintain | Apr 25, 2024 |
| Bernstein | Market Perform | Market Perform | Maintain | Oct 12, 2023 |
| Wolfe Research | Outperform | Outperform | Maintain | Nov 22, 2022 |
| Credit Suisse | Neutral | Neutral | Maintain | Nov 15, 2022 |
| Goldman Sachs | Neutral | Buy | Downgrade | Oct 10, 2022 |
| Independent Research | Buy | Hold | Upgrade | Jan 22, 2021 |
| Berenberg | Hold | Sell | Upgrade | Jan 24, 2019 |
| Bank of America | Buy | Buy | Maintain | Jan 8, 2019 |
| Macquarie | Outperform | Outperform | Maintain | Oct 22, 2018 |
| Atlantic Equities | Overweight | Overweight | Maintain | Sep 20, 2018 |
| B. Riley FBR | Neutral | Buy | Downgrade | May 5, 2018 |
| Stifel Nicolaus | Hold | Hold | Maintain | Apr 20, 2018 |
| Argus | Hold | Buy | Downgrade | Apr 20, 2018 |
| B. Riley Securities | Neutral | Buy | Downgrade | Mar 6, 2017 |
| SunTrust Robinson Humphrey | Hold | Buy | Downgrade | Dec 22, 2016 |
| CLSA | Outperform | Outperform | Maintain | Oct 26, 2016 |
| Argus Capital | Buy | Hold | Upgrade | Oct 12, 2016 |
| Johnson Rice | Buy | Accumulate | Maintain | Aug 26, 2016 |
| Sterne Agee CRT | Buy | Neutral | Upgrade | Feb 16, 2016 |
| Sterne Agee | Buy | Neutral | Upgrade | Feb 16, 2016 |
| GMP Securities | Hold | Hold | Maintain | Feb 3, 2016 |
| Hilliard Lyons | Neutral | Upgrade | Jun 4, 2015 | |
| Societe Generale | Hold | Buy | Downgrade | Apr 29, 2015 |
| BTIG Research | Neutral | Neutral | Maintain | Dec 30, 2014 |
| Canaccord Genuity | Hold | Buy | Downgrade | Nov 17, 2014 |
| Standpoint Research | Hold | Sell | Upgrade | Jan 31, 2014 |
| Exane BNP Paribas | Underperform | Underperform | Maintain | Sep 11, 2013 |
| Oracle Investment Research | Hold | Sell | Upgrade | May 24, 2013 |
| Tigress Financial | Neutral | Neutral | Maintain | Feb 25, 2013 |
| BMO Capital | Outperform | Outperform | Maintain | Oct 26, 2012 |
| Bank oferica | Buy | Buy | Maintain | Feb 28, 2012 |
Upside is calculated against the persisted previous close $148.63. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Analyst unavailable | $152 | $149.14 | +2.3% | Jul 21, 2026 |
| Bernstein | Analyst unavailable | $156 | $148.32 | +5.0% | Jun 11, 2026 |
| UBS | Analyst unavailable | $172 | $148.46 | +15.7% | Apr 27, 2026 |
| Deutsche Bank | Steve Powers | $163 | $148.63 | +9.7% | Apr 27, 2026 |
| Evercore ISI | Robert Ottenstein | $162 | $148.11 | +9.0% | Apr 27, 2026 |
| Wells Fargo | Analyst unavailable | $164 | $148.11 | +10.3% | Apr 27, 2026 |
| Barclays | Analyst unavailable | $146 | $143.86 | -1.8% | Apr 14, 2026 |
| RBC Capital | Analyst unavailable | $167 | $146.66 | +12.4% | Apr 9, 2026 |
| Piper Sandler | Analyst unavailable | $142 | $144.9 | -4.5% | Apr 8, 2026 |
| Wells Fargo | Analyst unavailable | $177 | $160.07 | +19.1% | Feb 17, 2026 |
| UBS | Analyst unavailable | $170 | $151.06 | +14.4% | Jan 23, 2026 |
| Wells Fargo | Chris Carey | $165 | $149.93 | +11.0% | Jan 23, 2026 |
| Barclays | Lauren Lieberman | $155 | $144.37 | +4.3% | Jan 16, 2026 |
| UBS | Peter Grom | $161 | $146.54 | +8.3% | Jan 14, 2026 |
| Piper Sandler | Analyst unavailable | $150 | $139.91 | +0.9% | Jan 7, 2026 |
| Wells Fargo | Analyst unavailable | $158 | $140.04 | +6.3% | Jan 5, 2026 |
| Jefferies | Analyst unavailable | $179 | $145.21 | +20.4% | Dec 16, 2025 |
| Barclays | Analyst unavailable | $151 | $143.45 | +1.6% | Dec 8, 2025 |
| Morgan Stanley | Analyst unavailable | $175 | $151.46 | +17.7% | Oct 27, 2025 |
| UBS | Peter Grom | $176 | $150.92 | +18.4% | Oct 8, 2025 |
| Barclays | Lauren Lieberman | $153 | $153.65 | +2.9% | Oct 1, 2025 |
| Barclays | Analyst unavailable | $164 | $152.88 | +10.3% | Jul 31, 2025 |
| UBS | Peter Grom | $180 | $154.94 | +21.1% | Jul 30, 2025 |
| Redburn Partners | Edward Lewis | $161 | $159.98 | +8.3% | May 1, 2025 |
| Morgan Stanley | Dara Mohsenian | $180 | $160.06 | +21.1% | Apr 25, 2025 |
| Barclays | Lauren Lieberman | $159 | $164.74 | +7.0% | Jan 23, 2025 |
| Jefferies | Kaumil Gajrawala | $174 | $175.68 | +17.1% | Dec 5, 2024 |
| Stifel Nicolaus | Mark Astrachan | $167 | $176.28 | +12.4% | Nov 22, 2024 |
| Truist Financial | Bill Chappell | $180 | $169.64 | +21.1% | Oct 21, 2024 |
| RBC Capital | Nik Modi | $164 | $169 | +10.3% | Oct 21, 2024 |
| D.A. Davidson | Linda Bolton Weiser | $160 | $169.02 | +7.6% | Oct 21, 2024 |
| Raymond James | Olivia Tong | $190 | $171.28 | +27.8% | Oct 21, 2024 |
| D.A. Davidson | Linda Bolton Weiser | $159 | $169.27 | +7.0% | Oct 9, 2024 |
| Goldman Sachs | Bonnie Herzog | $164 | $168.88 | +10.3% | Oct 4, 2024 |
| Barclays | Lauren Lieberman | $163 | $173.55 | +9.7% | Sep 30, 2024 |
| Piper Sandler | Korinne Wolfmeyer | $174 | $173.77 | +17.1% | Sep 23, 2024 |
| BNP Paribas | Kevin Grundy | $192 | $177.02 | +29.2% | Sep 16, 2024 |
| Jefferies | Kaumil Gajrawala | $175 | $165.93 | +17.7% | Jul 24, 2024 |
| Stifel Nicolaus | Mark Astrachan | $161 | $167.96 | +8.3% | Jul 22, 2024 |
| Evercore ISI | Robert Ottenstein | $183 | $169.44 | +23.1% | Jul 18, 2024 |
| Deutsche Bank | Steve Powers | $176 | $168.53 | +18.4% | Jul 17, 2024 |
| BNP Paribas | Kevin Grundy | $187 | $168.26 | +25.8% | Jun 24, 2024 |
| Argus Research | Chris Graja | $185 | $162.88 | +24.5% | Apr 25, 2024 |
| Barclays | Lauren Lieberman | $170 | $160.54 | +14.4% | Apr 23, 2024 |
| Bernstein | Alexia Howard | $40 | $151.38 | -73.1% | Nov 24, 2023 |
| Morgan Stanley | Dara Mohsenian | $174 | $146.26 | +17.1% | Oct 18, 2023 |
| Raymond James | Olivia Tong | $170 | $150.25 | +14.4% | Jan 13, 2023 |
| J.P. Morgan | Analyst unavailable | $150 | $149.86 | +0.9% | Jan 13, 2023 |
| Wells Fargo | Analyst unavailable | $168 | $150.62 | +13.0% | Jan 3, 2023 |
| Deutsche Bank | Analyst unavailable | $162 | $148.47 | +9.0% | Dec 6, 2022 |
| Wells Fargo | Analyst unavailable | $155 | $140.49 | +4.3% | Nov 16, 2022 |
| Credit Suisse | Analyst unavailable | $130 | $141.66 | -12.5% | Nov 15, 2022 |
| Raymond James | Olivia Tong | $155 | $124.43 | +4.3% | Oct 12, 2022 |
| Goldman Sachs | Jason English | $143 | $124.27 | -3.8% | Oct 9, 2022 |
| Wells Fargo | Analyst unavailable | $150 | $126.25 | +0.9% | Oct 3, 2022 |
| Barclays | Lauren Lieberman | $154 | $149.81 | +3.6% | Aug 18, 2022 |
| Truist Financial | Analyst unavailable | $160 | $142.6 | +7.6% | Aug 1, 2022 |
| J.P. Morgan | Analyst unavailable | $156 | $139.77 | +5.0% | Jul 21, 2022 |
| Deutsche Bank | Analyst unavailable | $157 | $135.81 | +5.6% | Jun 21, 2022 |
| Deutsche Bank | Steve Powers | $171 | $132.36 | +15.1% | Jun 19, 2022 |
| Wells Fargo | Chris Carey | $170 | $145.46 | +14.4% | Jun 6, 2022 |
| Barclays | Analyst unavailable | $157 | $141.79 | +5.6% | May 23, 2022 |
| Credit Suisse | Kaumil Gajrawala | $150 | $161.74 | +0.9% | Apr 26, 2022 |
| Barclays | Analyst unavailable | $176 | $161.39 | +18.4% | Apr 22, 2022 |
| Deutsche Bank | Analyst unavailable | $177 | $164.54 | +19.1% | Apr 21, 2022 |
| Raymond James | Analyst unavailable | $180 | $163.65 | +21.1% | Apr 21, 2022 |
| UBS | Peter Grom | $160 | $158.52 | +7.6% | Apr 19, 2022 |
| Raymond James | Olivia Tong | $175 | $159.49 | +17.7% | Apr 11, 2022 |
| Goldman Sachs | Jason English | $173 | $155.09 | +16.4% | Apr 1, 2022 |
| Truist Financial | Bill Chappell | $175 | $150.82 | +17.7% | Mar 23, 2022 |
| UBS | Peter Grom | $163 | $162 | +9.7% | Jan 20, 2022 |
| Morgan Stanley | Dara Mohsenian | $177 | $162 | +19.1% | Jan 20, 2022 |
| Stifel Nicolaus | Mark Astrachan | $148 | $161.13 | -0.4% | Jan 19, 2022 |
| Jefferies | Kevin Grundy | $187 | $161.13 | +25.8% | Jan 19, 2022 |
| Wells Fargo | Christopher Carey | $180 | $163.33 | +21.1% | Jan 5, 2022 |
| Bank of America Securities | Bryan Spillane | $160 | $137.73 | +7.6% | Oct 5, 2021 |
| Independent Research | Lars Lusebrink | $154 | $140.79 | +3.6% | Aug 4, 2021 |
| Credit Suisse | Kaumil Gajrawala | $145 | $140.25 | -2.4% | Aug 2, 2021 |
| DZ BANK AG | Michael Pohn | $119 | $133.58 | -19.9% | Apr 21, 2021 |
Track every rating change on PG the moment it posts. Free to start.
Start freeFollow PG with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompared to Q2 FY26, described as the softest quarter due to inventory and trade headwinds, Q3 showed improvement with broad-based organic growth across every category and region. The $1 billion after-tax cost headwind was newly quantified this quarter, attributed to Middle East geopolitical disruption affecting commodity, energy, and logistics costs. Management introduced specific restructuring details: a 15% non-manufacturing headcount reduction target over two years and Supply Chain 3.0 automation rollout across nine categories. Innovation emphasis shifted toward home care (Dawn Powerwash, Fairy Skip the Soak, Mr. Clean) and beauty (SK-II, Pantene), whereas Q2 emphasized baby care (Pampers Prestige) and laundry (Tide Evo, Downy Intense). FY26 guidance was maintained in both quarters, but Q3 added the caveat that EPS is expected toward the lower end of the range, a subtle but meaningful shift in tone.
FY26 guidance was maintained for the second consecutive quarter: organic sales growth of approximately +4%, core EPS of $6.83-$7.09, free-cash-flow productivity of 85-90%, and $15 billion in total cash returns to shareholders. The key delta is that management now expects full-year EPS to land toward the lower end of the range, reflecting the approximately $1 billion after-tax cost pressure from commodities, energy, and logistics. The 3% dividend increase and share repurchase program remain unchanged. Capex outlook continues to be increasing, consistent with the prior quarter's $10 billion capacity-investment plan.
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.